InCROM CHINA
Strengths
- Bases in Shanghai, Beijing, Chengdu, Guangzhou, and Hong Kong - minimise commuting burdens, allowing clients to have quick and easy access to our services
- Vast and rapidly growing clinical network - over 100 SFDA-approved hospitals and 9 labs
- Co-ownership of Japan-China Clinical Trial Centre of Hypertension (JCCTCH) with the prestigious Ruijin Hospital recognised for their outstanding achievements in hypertension research
- Majority of the staff are medical and/or pharmaceutical specialists
- In-house Chinese regulatory and pharmaceutical affairs specialists available
Services
- Submission support
- Selection of study site(s)
- Selection of (and negotiations with) investigator(s)
- Production of essential documents required by Chinese regulatories
- Subject recruitment and management
- Monitoring
- Data management (DM)
- Statistical Analysis (SA)
- Informed consent forms (IC) and case report forms (CRF)
- Consultation - regulatory affairs, feasibility, drug development in China, etc.
- Market research to help identify a product's market potential